M. Byrne

发表

Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.

G. Dore, P. Vickerman, J. Amin, 2021, The lancet. Gastroenterology & hepatology.

Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.

T. Rhodes, L. Degenhardt, K. Lancaster, 2022, The International journal on drug policy.

The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study

T. Rhodes, L. Degenhardt, K. Lancaster, 2022, Contemporary Drug Problems.

Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study

G. Dore, P. Vickerman, J. Amin, 2018 .

"You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.

A. Milat, G. Dore, C. Treloar, 2022, The International journal on drug policy.

Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C)

N. Martin, T. Butler, C. Treloar, 2021, Harm Reduction Journal.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

G. Dore, S. Nielsen, B. Larance, 2021, The International journal on drug policy.

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

G. Dore, S. Nielsen, B. Larance, 2020, BMJ Open.

Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons

G. Dore, J. Stone, A. Lim, 2021, Hepatology.

A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.

G. Dore, J. Grebely, A. Lloyd, 2023, Journal of hepatology.

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial

B. Larance, J. Grebely, M. Montebello, 2024, International Journal of Drug Policy.

Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study

P. Vickerman, J. Grebely, B. Hajarizadeh, 2023, Journal of viral hepatitis.